Patients with metastatic cancer who are treated with an anti-programmed death therapy are at an increased risk for neurological complications. READ MORE

News

In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors are more effective and safer than conventional second-line treatment

READ MORE

Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.

READ MORE

A systemic immune response, rather than a local response of a tumor, determines successful remission following cancer immunotherapy.

READ MORE

Research in Review

In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product.

READ MORE

Chimeric antigen receptor T-cells may elicit responses in solid cancers by inducing cancer cell death and the release of tumor antigens that could stimulate T-cell activity.

READ MORE

Pembrolizumab improves response to chimeric antigen receptor T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia.

READ MORE

Early activation of programmed cell death-1 in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer.

READ MORE